These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 9341960)

  • 1. Case history. 1: the use of epoetin alfa in delayed anaemia.
    Mertelsmann R
    Ann Oncol; 1997; 8 Suppl 3():S11-2. PubMed ID: 9341960
    [No Abstract]   [Full Text] [Related]  

  • 2. [Epoetin alfa: recent strategies of use].
    Tumori; 1997; 83(6):975-8. PubMed ID: 9537918
    [No Abstract]   [Full Text] [Related]  

  • 3. Case history. 2: The use of epoetin alfa before high-dose chemotherapy.
    Mertelsmann R
    Ann Oncol; 1997; 8 Suppl 3():S13. PubMed ID: 9341961
    [No Abstract]   [Full Text] [Related]  

  • 4. Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life.
    Hudis CA; Vogel CL; Gralow JR; Williams D;
    Clin Breast Cancer; 2005 Jun; 6(2):132-42. PubMed ID: 16001991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anemia and epoetin alfa in high-dose chemotherapy programs for breast cancer patients.
    Danova M; Ferrari S
    Semin Oncol; 2002 Jun; 29(3 Suppl 8):21-5. PubMed ID: 12082650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resource utilisation and time commitment associated with correction of anaemia in cancer patients using epoetin alfa.
    Lynch DM; Slaven T
    Clin Drug Investig; 2007; 27(9):661-2. PubMed ID: 17705574
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost of managing anemia with and without prophylactic epoetin alfa therapy in breast cancer patients receiving combination chemotherapy.
    Meadowcroft AM; Gilbert CJ; Maravich-May D; Hayward SL
    Am J Health Syst Pharm; 1998 Sep; 55(18):1898-902. PubMed ID: 9784769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.
    Senecal FM; Yee L; Gabrail N; Charu V; Tomita D; Rossi G; Schwartzberg L
    Clin Breast Cancer; 2005 Dec; 6(5):446-54. PubMed ID: 16381629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy-induced cognitive dysfunction: a clearer picture.
    O'Shaughnessy JA
    Clin Breast Cancer; 2003 Nov; 4 Suppl 2():S89-94. PubMed ID: 14705598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epoetin alfa: to give or not to give.
    Dang C; Hudis C; Norton L
    J Natl Cancer Inst; 2013 Jul; 105(14):1001-3. PubMed ID: 23860203
    [No Abstract]   [Full Text] [Related]  

  • 11. A multicenter study of recombinant human erythropoietin (epoetin alpha) in the management of anemia in cancer patients receiving chemotherapy.
    Pawlicki M; Jassem J; Bösze P; Lotan C; Kurteva GP; Siddiqui M; Kosmidis PA; Rigatos GA; Kansu E; Durkovic P; Aziz Z; Al Idrissi H; Roth A; Cozma G
    Anticancer Drugs; 1997 Nov; 8(10):949-57. PubMed ID: 9436638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer.
    Fagnoni P; Limat S; Chaigneau L; Guardiola E; Briaud S; Schmitt B; Merrouche Y; Pivot X; Woronoff-Lemsi MC
    Support Care Cancer; 2006 Oct; 14(10):1030-7. PubMed ID: 16802128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer.
    Martin SC; Gagnon DD; Zhang L; Bokemeyer C; Van Marwijk Kooy M; van Hout B
    Pharmacoeconomics; 2003; 21(16):1153-69. PubMed ID: 14594437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Italian gynecological consensus statement on the use of epoetin alfa in the management of anemia.
    Pecorelli S;
    Semin Oncol; 2002 Jun; 29(3 Suppl 8):13-5. PubMed ID: 12082648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice.
    Patton J; Reeves T; Wallace J
    Oncologist; 2004; 9(4):451-8. PubMed ID: 15266098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer.
    Welch RS; James RD; Wilkinson PM; Belli F; Cowan RA
    Cancer J Sci Am; 1995; 1(4):261-6. PubMed ID: 9166486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epoetin: for better or for worse?
    Lancet Oncol; 2004 Jan; 5(1):1. PubMed ID: 14700601
    [No Abstract]   [Full Text] [Related]  

  • 18. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
    Reed SD; Radeva JI; Daniel DB; Mody SH; Forlenza JB; McKenzie RS; Schulman KA
    Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoiesis stimulating agents: a personal journey.
    Leyland-Jones B
    J Natl Cancer Inst; 2013 Jul; 105(14):999-1001. PubMed ID: 23860202
    [No Abstract]   [Full Text] [Related]  

  • 20. Improvement in quality of life for cancer patients treated with epoetin alfa.
    Libretto SE; Barrett-Lee PJ; Branson K; Gorst DW; Kaczmarski R; McAdam K; Stevenson P; Thomas R
    Eur J Cancer Care (Engl); 2001 Sep; 10(3):183-91. PubMed ID: 11829381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.